No Data
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20
Lake Street analyst Frank Takkinen maintains $NeuroPace(NPCE.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 38.5% and a tot
NeuroPace to Participate in Two Healthcare Conferences in May
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in
NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript
Express News | Neuropace Inc : Morgan Stanley Cuts Target Price to $9.50 From $13.00
Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating
NeuroPace (NPCE) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $9.50 to $20.
Earnings Call Summary | NeuroPace(NPCE.US) Q1 2024 Earnings Conference
The following is a summary of the NeuroPace, Inc. (NPCE) Q1 2024 Earnings Call Transcript:Financial Performance:NeuroPace's Q1 2024 revenue increased by 25% to $18.1 million, including contributions f